Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

US7851463B2 · kind B2 · utility

Assignee

• Abbott GmbH & Co. KG · DE

Inventors

• Karla Drescher · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Liliane Unger · Ludwigshafen, DE
• Sean Colm Turner · Ludwigshafen, DE
• Wilfried Braje · Ludwigshafen, DE
• Roland Grandel · Dossenheim, DE
• Christophe Henry · Munich, DE
• Gisela Backfisch · Dossenheim, DE
• Armin Beyerbach · Bad Dürkheim, DE
• Wilfried Lubisch · Mannheim, DE

Key dates

• Filing date: Oct 14, 2005
• Grant date: Dec 14, 2010
• Expiry date: Oct 14, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of the formula (I). The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.